Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Open Access
- 1 June 2016
- journal article
- editorial
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 40 (3) , 193-195
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeNew England Journal of Medicine, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trialAmerican Heart Journal, 2013
- MethodsCanadian Journal of Diabetes, 2013
- Basal Insulin and Cardiovascular and Other Outcomes in DysglycemiaNew England Journal of Medicine, 2012
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- New-Onset Diabetes and Risk of All-Cause and Cardiovascular MortalityDiabetes Care, 2006